vs
Side-by-side financial comparison of OP Bancorp (OPBK) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $24.3M, roughly 1.2× OP Bancorp). On growth, OP Bancorp posted the faster year-over-year revenue change (13.7% vs -67.6%).
OP Bancorp is the bank holding company for Open Bank, a community-oriented commercial bank headquartered in California, United States. It provides a full range of banking solutions including deposit accounts, commercial real estate loans, small business financing, and consumer lending products, primarily catering to small and medium-sized enterprises, local immigrant communities, and retail clients across Southern California.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
OPBK vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $24.3M | $28.1M |
| Net Profit | — | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | 39.2% | -147.6% |
| Net Margin | — | -147.1% |
| Revenue YoY | 13.7% | -67.6% |
| Net Profit YoY | — | -182.8% |
| EPS (diluted) | $0.48 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $24.3M | $28.1M | ||
| Q3 25 | $24.5M | $32.5M | ||
| Q2 25 | $23.7M | $15.7M | ||
| Q1 25 | $22.2M | $8.0M | ||
| Q4 24 | $21.3M | $86.6M | ||
| Q3 24 | $20.7M | $2.1M | ||
| Q2 24 | $20.4M | $500.0K | ||
| Q1 24 | $19.6M | $0 |
| Q4 25 | — | $-41.3M | ||
| Q3 25 | $6.7M | $-51.2M | ||
| Q2 25 | $6.3M | $-44.9M | ||
| Q1 25 | $5.6M | $-33.9M | ||
| Q4 24 | — | $49.9M | ||
| Q3 24 | $5.4M | $-19.1M | ||
| Q2 24 | $5.4M | $-12.5M | ||
| Q1 24 | $5.2M | $-10.3M |
| Q4 25 | 39.2% | -147.6% | ||
| Q3 25 | 39.5% | -163.7% | ||
| Q2 25 | 35.7% | -302.9% | ||
| Q1 25 | 34.6% | -466.3% | ||
| Q4 24 | 31.2% | 54.5% | ||
| Q3 24 | 36.5% | -1051.6% | ||
| Q2 24 | 37.2% | -3068.0% | ||
| Q1 24 | 37.1% | — |
| Q4 25 | — | -147.1% | ||
| Q3 25 | 27.4% | -157.4% | ||
| Q2 25 | 26.7% | -285.6% | ||
| Q1 25 | 25.0% | -425.7% | ||
| Q4 24 | — | 57.7% | ||
| Q3 24 | 26.2% | -925.0% | ||
| Q2 24 | 26.7% | -2503.2% | ||
| Q1 24 | 26.7% | — |
| Q4 25 | $0.48 | $-0.41 | ||
| Q3 25 | $0.45 | $-0.52 | ||
| Q2 25 | $0.42 | $-0.46 | ||
| Q1 25 | $0.37 | $-0.35 | ||
| Q4 24 | $0.33 | $0.52 | ||
| Q3 24 | $0.36 | $-0.20 | ||
| Q2 24 | $0.36 | $-0.13 | ||
| Q1 24 | $0.34 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.3M | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $227.9M | $114.3M |
| Total Assets | $2.7B | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.3M | $245.0M | ||
| Q3 25 | $166.7M | $288.2M | ||
| Q2 25 | $205.4M | $240.1M | ||
| Q1 25 | $198.9M | $275.7M | ||
| Q4 24 | $134.9M | $314.0M | ||
| Q3 24 | $166.8M | $204.6M | ||
| Q2 24 | $127.7M | $218.7M | ||
| Q1 24 | $139.2M | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $227.9M | $114.3M | ||
| Q3 25 | $221.5M | $147.7M | ||
| Q2 25 | $213.7M | $192.3M | ||
| Q1 25 | $210.1M | $229.0M | ||
| Q4 24 | $205.0M | $256.8M | ||
| Q3 24 | $203.6M | $201.0M | ||
| Q2 24 | $195.9M | $215.2M | ||
| Q1 24 | $194.7M | $223.9M |
| Q4 25 | $2.7B | $327.7M | ||
| Q3 25 | $2.6B | $372.8M | ||
| Q2 25 | $2.6B | $313.5M | ||
| Q1 25 | $2.5B | $327.3M | ||
| Q4 24 | $2.4B | $351.2M | ||
| Q3 24 | $2.4B | $217.6M | ||
| Q2 24 | $2.3B | $222.0M | ||
| Q1 24 | $2.2B | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.2M | $-43.5M |
| Free Cash FlowOCF − Capex | $23.4M | — |
| FCF MarginFCF / Revenue | 96.2% | — |
| Capex IntensityCapex / Revenue | 11.5% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.2M | $-43.5M | ||
| Q3 25 | $23.9M | $-47.0M | ||
| Q2 25 | $-7.0M | $-39.6M | ||
| Q1 25 | $5.6M | $-40.7M | ||
| Q4 24 | $31.2M | $42.0M | ||
| Q3 24 | $13.3M | $-14.5M | ||
| Q2 24 | $15.8M | $-7.3M | ||
| Q1 24 | $-3.2M | $-6.7M |
| Q4 25 | $23.4M | — | ||
| Q3 25 | $23.4M | $-47.2M | ||
| Q2 25 | $-7.7M | $-39.6M | ||
| Q1 25 | $4.2M | $-40.8M | ||
| Q4 24 | $29.7M | $41.7M | ||
| Q3 24 | $12.8M | $-14.6M | ||
| Q2 24 | $15.7M | $-7.3M | ||
| Q1 24 | $-3.2M | $-6.8M |
| Q4 25 | 96.2% | — | ||
| Q3 25 | 95.6% | -145.4% | ||
| Q2 25 | -32.5% | -252.2% | ||
| Q1 25 | 19.0% | -512.1% | ||
| Q4 24 | 139.0% | 48.2% | ||
| Q3 24 | 61.5% | -706.3% | ||
| Q2 24 | 77.0% | -1463.4% | ||
| Q1 24 | -16.6% | — |
| Q4 25 | 11.5% | 0.0% | ||
| Q3 25 | 2.3% | 0.6% | ||
| Q2 25 | 3.0% | 0.3% | ||
| Q1 25 | 6.4% | 1.1% | ||
| Q4 24 | 7.3% | 0.3% | ||
| Q3 24 | 2.8% | 6.8% | ||
| Q2 24 | 0.4% | 7.6% | ||
| Q1 24 | 0.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | 3.57× | — | ||
| Q2 25 | -1.10× | — | ||
| Q1 25 | 1.02× | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | 2.45× | — | ||
| Q2 24 | 2.90× | — | ||
| Q1 24 | -0.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OPBK
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
